Patrick Griggs v. Vital Therapies Inc.; Terry Winters; Michael Swanson

     Vital Therapies misrepresented the development of its liver-failure treatment, and shares plunged 73.4 percent, closing at $3.65 a share, after the truth was revealed in August, a class claims.

%d bloggers like this: